Fortrea Holdings (FTRE) Other Non-Current Assets (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Other Non-Current Assets came in at $91.8 million in Q2 2026, down 9.38% YoY from $101.3 million in Q2 2025, and up 6.62% on a QoQ basis from $86.1 million in Q1 2026.
Fortrea Holdings (FTRE) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Other Non-Current Assets data on file, last reported at $91.8 million in Q2 2026.
- Quarterly Other Non-Current Assets fell 9.38% year-over-year to $91.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $91.8 million (down 9.38% YoY) and the FY2025 annual result came in at $80.8 million, down 21.86% from the prior year.
- Other Non-Current Assets improved to $91.8 million in Q2 2026, from $86.1 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $368.8 million in Q4 2023 to a low of $54.3 million in Q4 2022.
- A 5-year average of $124.0 million and a median of $89.0 million in 2026 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets soared 579.19% — and 2024, when it sank 71.96%.
- Tracing FTRE's Other Non-Current Assets over 5 years: stood at $54.3 million in 2022, then soared by 579.19% to $368.8 million in 2023, then slumped by 71.96% to $103.4 million in 2024, then slipped by 21.86% to $80.8 million in 2025, then climbed by 13.61% to $91.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $91.8 million (Q2 2026), $86.1 million (Q1 2026), and $80.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 91.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.80 Mn |
| Mar 31, 2026 | 86.10 Mn |
| Dec 31, 2025 | 80.80 Mn |
| Sep 30, 2025 | 74.20 Mn |
| Jun 30, 2025 | 101.30 Mn |
| Mar 31, 2025 | 101.40 Mn |
| Dec 31, 2024 | 103.40 Mn |
| Sep 30, 2024 | 92.30 Mn |
| Jun 30, 2024 | 83.80 Mn |
| Mar 31, 2024 | 345.10 Mn |
| Dec 31, 2023 | 368.80 Mn |
| Sep 30, 2023 | 69.70 Mn |
| Jun 30, 2023 | 83.70 Mn |
| Dec 31, 2022 | 54.30 Mn |